fda requirements for clinical trials and market approval
TRANSCRIPT
![Page 1: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/1.jpg)
FDA Requirements for Clinical Trials and Market Approval
Carl Peck MD
Adj. Professor, UCSF
Chairman, NDA Partners LLC
Carl Peck 2016
![Page 2: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/2.jpg)
Carl Peck 2016
Why, What, How, When ?
FDA Requirements
![Page 3: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/3.jpg)
Patent Medicine 1900 All Medicines sold without a prescription
Children and Adults die after taking cough syrup
arsenic, opium, insect parts, acetanilid, hydrochloric acid, red wine
![Page 4: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/4.jpg)
1906 Pure Food and Drug Act
–“The Jungle”
–Prohibited adulterated or misbranded foods or drugs
–Regulated labeling
• “false or misleading”
![Page 5: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/5.jpg)
The “Elixir of Sulfanilamide” Incident
In 1937: a chemist @ Massengill Co. used sweet-tasting diethylene glycol (antifreeze) in sulfa drug syrup form to improve taste
– Diethylene glycol is sweet but deadly
– > 100 deaths, most were children
– Company fined $300
– Chemist committed suicide
Public outrage led to passage of 1938 Food Drug & Cosmetic Act
![Page 6: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/6.jpg)
1938 Food Drug & Cosmetic Act
• Prohibited false therapeutic claims
• some drugs by prescription only
• Increased factory inspections
Carl Peck 2016
![Page 7: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/7.jpg)
Thalidomide
FDA did not approve for U.S
17 known U.S. cases of limb defects
• Sedative for pregnant women
• 1000’s of babies born with limb defects in
Europe and elsewhere
![Page 8: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/8.jpg)
1962 Kefauver-Harris Amendments
• Public concern about thalidomide
• Required “substantial evidence” of effectiveness, and safe
– “substantial evidence” = based on evidence consisting of adequate and well-controlled
investigations
Carl Peck 2016
![Page 9: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/9.jpg)
“substantial evidence” of effectiveness
“evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could be fairly and responsibly concluded by such experts that the drug will have the effect it purports or as represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof.”
2+ independent, confirmatory clinical trials P < 0.05
Carl Peck 2016
![Page 10: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/10.jpg)
FDA Today n=12,000; $ 12 B
Carl Peck 2016
![Page 11: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/11.jpg)
Carl Peck 2016
![Page 12: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/12.jpg)
FDA Regulated Therapeutic
Products for Human Use • Small molecules
– New molecular entities – Generic – Similar but not bioequivalent (505(b)(2))
• Biologics – Proteins – Blood products – Vaccines
–Biosimilars • Medical devices • Drug/biologic - Device Combinations
Carl Peck 2016
![Page 13: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/13.jpg)
Carl Peck 2016
What are FDA Requirements
• Standards
– CMC
– animal pharm/tox
– human clinical trials
• Ethics
• Effectiveness
• Labeling
– INDs, & NDAs
– Post-approval safety monitoring
![Page 14: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/14.jpg)
Biosimilars Biologics Price Competition Act, 2009
(BCPI)
• Requirements - General – “highly similar” vs “interchangeable”
– “no clinically meaningful difference” • Safety, purity, potency
• Requirements – Specific – Analytical
– Animal
– Clinical PK and PD
• 1st Approval in 2015: Zarxio (filgrastim-sndz)
Carl Peck 2016
![Page 15: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/15.jpg)
How does FDA communicate and Enforce its Requirements ?
• Guidance – Meetings – Guidance documents
• Review –
– IND’s – NDA’s, BLA’s, IDE’s – pharmacovigilance
• Enforcement – drug quality, safety
– Inspections
– Advertising and promotion
Carl Peck 2016
![Page 16: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/16.jpg)
Meetings with FDA n = 2800 (2015)
• Type A – immediately necessary
– Clinical Holds, Special Protocol Assessments, Disputes
• 15-20 days of request
• Type B (milestone)
– Pre-IND, End of Phase 2a, 2, Pre-NDA/BLA
• Information package due 30 days prior to meeting
• 60 days
• FDA written response prior to meeting
• Type C (Everything else)
– General advice
• 75 Days
Carl Peck 2016
![Page 17: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/17.jpg)
Carl Peck 2016
• Written guidances – Regulations, guidelines (incl. ICH),
– guidances (>500), not binding
– Literature publications
• Face-to-face & telephonic meetings – Pre-IND, EoP2a, EoP2a Clinical Pharmacology, pre-
NDA, others as-needed
• FDA Advisory Committee meetings
• Presentations & publications Website - www.fda.gov
FDA Guidance
![Page 18: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/18.jpg)
Carl Peck 2016
When does FDA engage?
![Page 19: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/19.jpg)
FDA Decisions
• driven by scientific and risk/benefit evaluations,
precedents, policies
– societal safety and benefit
– regulators’ personal philosophies
• Influence of public Advisory Committees
• Political and media influences can influence
Carl Peck 2016
![Page 20: FDA Requirements for Clinical Trials and Market Approval](https://reader031.vdocument.in/reader031/viewer/2022012017/615b7fe8d16a4d631262296a/html5/thumbnails/20.jpg)
End of Presentation
Carl Peck 2016